Entinostat

Drug Profile

Entinostat

Alternative Names: EDP-103; KHK-2375; MS-27-275; MS-275; SNDX-275

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator Nihon Schering; Pfizer; University of Tokyo
  • Developer Eddingpharm; Genentech; Kyowa Hakko Kirin; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Pfizer; Roswell Park Cancer Institute; Syndax Pharmaceuticals
  • Class Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II Colorectal cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
  • Preclinical Pancreatic cancer
  • Phase Unknown Endometrial cancer

Most Recent Events

  • 23 Jun 2017 CTP push NCT03179930 - qualifiers corrected
  • 22 Jun 2017 Syndax Pharmaceuticals plans a pharmacokinetics phase I trial in USA (NCT03192111)
  • 10 Jun 2017 Adverse events and efficacy data from a Phase-II ENCORE 601 trial in Advanced melanoma (Combination therapy, Late-stage disease, Metastatic disease) released by Syndax Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top